Although the open-label trial has many limitations, it could add some support to findings from the REDUCE-IT study, which showed a reduction in cardiovascular events with high-dose eicosapentaenoic acid.
Among patients with intermediate coronary lesions not undergoing revascularization, prediabetes, as defined by the International Expert Committee, best predicted increased risk for cardiovascular events.
A new study of medical records adds to the evidence linking gout, particularly in patients with poorly controlled serum urate level, to cardiovascular risk.
Patients with COVID-19 have an elevated risk for cardiovascular events and death, particularly if hospitalized, a retrospective analysis suggests. The risk was higher in the first 30 days after infection.